---
figid: PMC6770221__genes-10-00657-g006
figtitle: Mechanism of optimal therapeutic drugs in each subtype of breast cancer
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC6770221
filename: genes-10-00657-g006.jpg
figlink: /pmc/articles/PMC6770221/figure/genes-10-00657-f006/
number: F6
caption: The mechanism of optimal therapeutic drugs in each subtype of breast cancer.
  Sorafenib, Paclitaxel, and Vincristine were applicable for the basal-like subtype
  treatment, Irinotecan was optimum for the her2-enriched subtype treatment, Vemurafenib
  was suitable for the luminal A subtype treatment, and Vorinostat was applied to
  the luminal B subtype treatment.
papertitle: Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision
  drugs for Breast Cancer Patients.
reftext: Yingqi Xu, et al. Genes (Basel). 2019 Sep;10(9):657.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.737186
figid_alias: PMC6770221__F6
figtype: Figure
redirect_from: /figures/PMC6770221__F6
ndex: 5f3cb641-df30-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6770221__genes-10-00657-g006.html
  '@type': Dataset
  description: The mechanism of optimal therapeutic drugs in each subtype of breast
    cancer. Sorafenib, Paclitaxel, and Vincristine were applicable for the basal-like
    subtype treatment, Irinotecan was optimum for the her2-enriched subtype treatment,
    Vemurafenib was suitable for the luminal A subtype treatment, and Vorinostat was
    applied to the luminal B subtype treatment.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MIR324
  - BRAF
  - RAF1
  - RNASE3
  - JUN
  - JUNB
  - JUND
  - MIR148A
  - KDR
  - PPARA
  - PPARD
  - PPARG
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - ABO
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - TP53
  - TP63
  - TP73
  - ABCB6
  - ERBB2
  - TMEM43
  - MIR425
  - ALB
  - IER3IP1
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - TGFB1
  - TGFB2
  - TGFB3
  - PDGFRB
  - CYP2B6
  - RPE65
  - UVRAG
  - CKAP4
  - MIR23A
  - MIR22
  - Raf
  - Jra
  - CycE
  - cyc
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Stat92E
  - hop
  - bsk
  - abo
  - ABO-2R
  - ABO-X
  - ABO-YL
  - ABO-YS
  - p53
  - betaTub60D
  - hth
  - SRPK
  - Med
  - so
  - ana
  - Hrb27C
  - Rpt5
  - DCTN2-p50
  - dpp
  - put
  - mir-193
  - Cyp4g1
  - Cyp4d1
  - Cyp4d2
  - Cyp4ae1
  - Cyp18a1
  - Cpr
  - Cyp4e3
  - Cyp6a2
  - Cyp9b1
  - Cyp9b2
  - Cyp4e2
  - Cyp6a9
  - Cyp6a20
  - Cyp6a21
  - Cyp6a8
  - Cyp9c1
  - Cyp4d8
  - Cyp12a4
  - Cyp4c3
  - Cyp4e1
  - Cyp4p1
  - Cyp6a22
  - ref(2)P
  - wash
  - SH3PX1
  - mr
  - braf
  - si:dkey-222f8.3
  - raf1a
  - jun
  - kdr
  - kdrl
  - kita
  - ngfra
  - stat1b
  - stat4
  - gbgt1l5
  - tp53
  - her2
  - nfkb1
  - pdgfrb
  - tp63
  - Paclitaxel
  - Sorafenib
  - Vinblastine
  - Tryptophan
  - Reinol
  - Calcium
  - Glycine
  - serine
  - threonine
  - Progesterone
  - Retinol
  - Fatty acid
  - Vemurafenib
  - Irinotecan
  - Tryptaphan
  - reonine
  - Phenylalanine
  - Steroid
  - Tyrosine
  - Malaria
  - Amoebiasis  Amoebiasis
  - erythematosus
  - meiosis Systenic lupus erythematosus
  - Pancreatic secretion
  - lupus erythematosus
  - cancer
  - lupus eryhematoss
---
